Research Article
The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD
Table 2
One-year outcomes of switching to brolucizumab with and without the loading dose regimen in nAMD patients.
| | | Loading group (n = 13) | Nonloading group (n = 13) | |
| | Baseline, mean (SD) | | | | | BCVA (logMAR) | 0.28 (0.25) | 0.25 (0.20) | 0.98 | | CRT (µm) | 263.6 (40.7) | 244.9 (77.2) | 0.14 | | SFCT (µm) | 203.7 (89.8) | 164.1 (73.0) | 0.28 | | Outcome, mean (SD) | | | | | BCVA (logMAR) | 0.19 (0.28) | 0.23 (0.25) | 0.59 | | CRT (µm) | 221.7 (54.6) | 221.0 (78.7) | 0.41 | | SFCT (µm) | 193.5 (93.7) | 151.8 (69.3) | 0.2 | | Change, mean (SD) | | | | | BCVA (logMAR) | −0.09 (0.14) | −0.03 (0.13) | 0.32 | | CRT (µm) | −41.9 (66.6) | −23.9 (87.3) | 0.64 | | SFCT (µm) | −10.2 (21.6) | −12.2 (11.4) | 0.74 | | Dry macular, number (%) | 9 (69.2) | 9 (69.2) | 1.00 | | Number of injections, mean (SD) | 7.6 (0.6) | 6.8 (0.4) | 0.001† | | Injection interval (week), mean (SD) | 9.2 (2.5) | 9.5 (2.4) | 0.51 |
|
|
